| Nov 20 |
Nurix Therapeutics Receives PRIME Designation from the European Medicines Agency for NX-5948 for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia
|
| Nov 17 |
Nurix Therapeutics Presents Preclinical Data from Two Autoimmune and Inflammatory Disease Programs, NX-5948 and GS-6791, at ACR Convergence 2024
|
| Nov 5 |
Nurix Therapeutics Announces Presentations at the 66th American Society of Hematology (ASH) Annual Meeting
|
| Oct 21 |
Nurix Therapeutics Announces Presentations at the 7th Annual TPD & Induced Proximity Summit
|
| Oct 21 |
Nurix Therapeutics’ NX-5948 shows promise in Waldenstrom’s macroglobulinaemia trial
|
| Oct 19 |
Nurix Therapeutics Presents Positive Results from the Ongoing Clinical Trial of Its BTK Degrader NX-5948 in Patients with Relapsed/Refractory Waldenstrom’s Macroglobulinemia
|
| Oct 16 |
Nurix Therapeutics Expands Its Board of Directors with the Addition of Drug Commercialization Expert Anil Kapur
|
| Oct 14 |
Boeing, Nurix Therapeutics And 3 Stocks To Watch Heading Into Monday
|
| Oct 14 |
Nurix Therapeutics GAAP EPS of -$0.67 beats by $0.05, revenue of $12.6M misses by $2.04M
|
| Oct 11 |
Nurix Therapeutics, Inc. (NRIX) Reports Q3 Loss, Lags Revenue Estimates
|
